Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1163 - 1168
Section III - Un futur en développement
Published online 15 December 2009
  1. LEEM Biotech et Genopole. Bioproduction 2008, état des lieux et recommandations pour l’attractivité de la France. Rapport de synthèse, 2008. [Google Scholar]
  2. Cochet O, Chartrain M. Les systèmes mammaliens de production actuels qui sont agréés. Med Sci (Paris) 2009; 25 : 1078–83. [Google Scholar]
  3. Kelley B. Very large scale monoclonal antibody purification : the case for conventional unit operations. Biotechnol Prog 2007; 23 : 995–1008. [Google Scholar]
  4. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and fc-fusion proteins. Curr Pharm Biotechnol 2008; 9 : 482–501. [Google Scholar]
  5. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278 : 3466–73. [Google Scholar]
  6. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metast Rev 2005; 24 : 501–19. [Google Scholar]
  7. Harmsen MM, de Haard HJ. Properties, production and applications of camelid single chain antibodies fragments. Appl Microbiol Biotechnol 2007; 77 : 13–22. [Google Scholar]
  8. Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004; 22 : 1409–14. [Google Scholar]
  9. Ogunjimi AA, Chandler JM, Gooding CM, et al. High-level secretory expression of immunologically active intact antibody from the yeast Pichia pastoris. Biotechnol Lett 1999; 21 : 561–7. [Google Scholar]
  10. Ward M, Lin C, Victoria DC, et al. Characterization of humanized antibodies secreted by Aspergillus niger. Appl Environ Microbiol 2004; 70 : 2567–76. [Google Scholar]
  11. Jigami Y. Yeast glycobiology and its application. Biosci Biotechnol Biochem 2008; 72 : 637–48. [Google Scholar]
  12. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast : the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 : 387–92. [Google Scholar]
  13. Maras M, De Bruyn A, Vervecken W, et al. In vivo synthesis of complex N-glycans by expression of human N-acetylglucosaminyltransferase I in the filamentous fungus Trichoderma reesei. FEBS Lett 1999; 452 : 365–70. [Google Scholar]
  14. Edelman L, Margaritte C, Chaabihi H, et al. Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system. Immunology 1997; 9 : 13–9. [Google Scholar]
  15. Altmann F, Staudacher E, Wilson IB, März L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J 1999; 16 : 109–23. [Google Scholar]
  16. Hsu TA, Takahashi N, Tsukamoto Y, et al. Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells. J Biol Chem 1997; 272 : 9062–70. [Google Scholar]
  17. Harrison RL, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce “mammalianized” recombinant glycoproteins. Adv Virus Res 2006; 68 : 159–91. [Google Scholar]
  18. O’Connell KP, Kovaleva E, Campbell JH, et al. Production of a recombinant antibody fragment in whole insect larvae. Mol Biotechnol 2007; 36 : 44–51. [Google Scholar]
  19. Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants : an overview. Transgenic Res 2007; 16 : 315–32. [Google Scholar]
  20. Gomord V, Chamberlain P, Jefferis R, et al. Biopharmaceutical production in plants : problems, solutions and opportunities. Trends Biotechnol 2005; 23 : 559–65. [Google Scholar]
  21. Frey AD, Karg SR, Kallio PT. Expression of rat beta(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum remodels the plant-specific N-glycosylation. Plant Biotechnol J 2009; 7 : 33–48. [Google Scholar]
  22. Vézina LP, Faye L, Lerouge P, et al. Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 2009; 7 : 442–55. [Google Scholar]
  23. Hellwig S, Drossard J, Twyman RM, et al. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004; 22 : 1415–22. [Google Scholar]
  24. Cadoret JP, Bardor M, Lerouge P, et al. Microalgae as cell factories producing recombinant commercial proteins. Med Sci (Paris) 2008; 24 : 375–82. [Google Scholar]
  25. Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24 : 1591–7. [Google Scholar]
  26. Schuster M, Jost W, Mudde GC, et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007; 2 : 700–8. [Google Scholar]
  27. Houdebine LM. Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2008. Epub Feb 1. [Google Scholar]
  28. Tang B, Yu S, Zheng M, et al. High level expression of a functional human/mouse chimeric anti-CD20 monoclonal antibody in milk of transgenic mice. Transgenic Res 2008; 17 : 727–32. [Google Scholar]
  29. Raju TS, Briggs JB, Borge SM, et al. Species-specific variation in glycosylation of IgG : evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10 : 477–86. [Google Scholar]
  30. Zhu L, van de Lavoir MC, Albanese J, et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 2005; 23 : 1159–69. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.